Direkt zum Inhalt

Pischke, Sven ; Hardtke, Svenja ; Bode, Ulrike ; Birkner, Stephan ; Chatzikyrkou, Christos ; Kauffmann, Wolfgang ; Bara, Christoph L. ; Gottlieb, Jens ; Wenzel, Juergen ; Manns, Michael P. ; Wedemeyer, Heiner

Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience

Article

Pischke, Sven, Hardtke, Svenja, Bode, Ulrike, Birkner, Stephan, Chatzikyrkou, Christos, Kauffmann, Wolfgang, Bara, Christoph L., Gottlieb, Jens, Wenzel, Juergen , Manns, Michael P. and Wedemeyer, Heiner (2013) Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver International 33 (5), pp. 722-726.

DOI to cite this document: 10.5283/epub.37516


Abstract

Background The role of ribavirin for treatment of severe acute or chronic hepatitis E virus (HEV) infection is not well defined. Aims To investigate the applicability and efficacy of ribavirin therapy in acute and chronic HEV infections within a large single-centre cohort. Materials & Methods Clinical courses of forty-four German HEV-infected individuals were analysed. Results In a prospective ...

Background The role of ribavirin for treatment of severe acute or chronic hepatitis E virus (HEV) infection is not well defined. Aims To investigate the applicability and efficacy of ribavirin therapy in acute and chronic HEV infections within a large single-centre cohort. Materials & Methods Clinical courses of forty-four German HEV-infected individuals were analysed. Results In a prospective case series, we observed spontaneous recovery from acute symptomatic HEV-infection in 10/11 immunocompetent individuals. Ribavirin therapy was initiated in one patient with severe acute HEV-genotype-1e infection who rapidly improved liver function and cleared HEV. Of 15 organ transplant recipients with prolonged HEV viraemia, reduction in immunosuppression led to HEV-clearance in three patients, while ribavirin therapy was initiated in 11 subjects. A rapid response with undetectable HEV-RNA occurred in nine subjects. One patient died after experiencing a virological breakthrough associated with ribavirin dose reduction because of severe anaemia. Discussion Ribavirin is a safe treatment option for HEV infections. However, the optimal dose of ribavirin for the treatment of chronic hepatitis E remains to be determined as treatment failure may occur.



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleLiver International
PublisherWILEY
Place of PublicationHOBOKEN
Volume33
Number of Issue or Book Chapter5
Page Rangepp. 722-726
Date2013
Date of publication09 Aug 2018 12:54
InstitutionsMedicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene
Identification Number
ValueType
10.1111/liv.12114DOI
23489973PubMed ID
KeywordsE VIRUS-INFECTION; LIVER-TRANSPLANT RECIPIENTS; THERAPY; acute liver failure; hepatitis E; HEV; ribavirin; transplantation; treatment
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgPartially
Item ID37516

Export bibliographical data

Owner only: item control page

nach oben